Novel G protein-coupled receptor, GAVE7
OwnerHaifeng Eishingdrelo, Jidong Cai +1inventors
InventorsHaifeng Eishingdrelo, Jidong Cai, Ali Ardati
Life of this patent
Estimating the term…
Abstract
Novel GAVE7 polypeptides, proteins and nucleic acid molecules are provided. In addition to isolated, full-length GAVE7 proteins, isolated GAVE7 fusion proteins, antigenic peptides and anti-GAVE7 antibodies are taught. GAVE7, recombinant expression vectors, host cells into that the expression vectors have been introduced and non-human transgenic animals in that a GAVE7 gene has been introduced or disrupted are taught. Diagnostic, screening and therapeutic methods utilizing compositions of the invention also are provided.
Claims25
An isolated nucleic acid comprising the nucleotide sequence of GAVE7 (SEQ ID NO:
- 1) or a variant of GAVE7.
An isolated nucleic acid comprising a sequence that encodes a GAVE7 polypeptide with the amino acid sequence of SEQ ID NO:
- 2.
An isolated nucleic acid comprising an allelic variant of the nucleotide sequence of GAVE7 (SEQ ID NO:
- 1).
An isolated nucleic acid comprising a sequence that hybridizes under stringent conditions to a hybridization probe that is complementary to SEQ ID NO:
- 1 or complementary to a nucleic acid encoding SEQ ID NO:
- 2 and wherein said probe comprises a fragment of SEQ ID NO:
- 1 or a nucleic acid encoding SEQ ID NO:
- 2.
An isolated nucleic acid comprising a sequence that encodes a polypeptide, the amino acid sequence of that is at least 30% identical to SEQ ID NO:
- 1.
A purified polypeptide, the amino acid sequence of that comprises SEQ ID NO:
- 2.
A purified polypeptide comprising the third intracellular loop as set forth in SEQ ID NO:
- 2.
An antibody that binds specifically to GAVE7.
A therapeutic method for modulating GAVE7 signaling activity or signal transduction in a patient in need of treatment comprising administering to said patient an agonist, an antagonist or an inverse agonist of GAVE7.
A method for identifying an agonist of GAVE7 comprising:
- contacting a potential agonist with a cell expressing GAVE7 and determining whether in the presence of said potential agonist the signaling activity of GAVE7 is increased relative to the activity of GAVE7 in the absence of said potential agonist.
A method for identifying an inverse agonist of GAVE7 comprising:
- contacting a potential inverse agonist with a cell expressing GAVE7 and determining whether in the presence of said potential inverse agonist, the activity of GAVE7 is decreased relative to the activity of GAVE7 in the absence of said potential inverse agonist, and is decreased in the presence of an endogenous ligand or agonist.
A method for identifying an antagonist of GAVE7 comprising:
- contacting a potential antagonist with a cell expressing GAVE7 and determining whether in the presence of said potential antagonist the signaling activity of GAVE7 is decreased relative to the activity of GAVE7 in the presence of an endogenous ligand or agonist.
A therapeutic composition comprising an agonist an antagonist or an inverse agonist of GAVE7 capable of modulating GAVE7 signaling activity or transduction.
A method for treating a disease comprising administering to a patient in need of treatment a therapeutic composition comprising an agonist, an antagonist or an inverse agonist of GAVE7 capable of modulating GAVE7 signaling activity or transduction.
Dependencies are inferred from the claim text.